VCAM1

New Research Shows Potential Role for Mangos in Supporting Vascular Health and Antioxidant Activities

Retrieved on: 
Tuesday, August 1, 2023

BOSTON, Aug. 1, 2023 /PRNewswire/ -- Mangos are one of the most popular fruits1 in the world, grown in more than 100 countries2 globally and consumed by an extremely diverse population. Now, two new studies funded by the National Mango Board and presented as posters during the American Society for Nutrition's Annual Conference (Nutrition 2023) show mangos may play a role in risk reductions for vascular issues while helping to improve antioxidant levels among relatively healthy adult men and women who are overweight or obese.

Key Points: 
  • Mangos are one of the most popular fruits in the world, grown in 100+ countries and consumed by a diverse population.
  • "It's likely the unique matrix of vitamins and bioactive compounds synergistically working together that resulted in our findings," says Young Hong.
  • Following the first 12 weeks, participants took a 4-week washout break then switched groups and consumed the alternate snack for another 12 weeks.
  • Findings from the second study show a significant increase of glutathione peroxidase (GPX), a powerful antioxidant enzyme.

Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University

Retrieved on: 
Monday, May 23, 2022

ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research agreement with the Queensland University of Technology (QUT), Australia.

Key Points: 
  • ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research agreement with the Queensland University of Technology (QUT), Australia.
  • Quoin will fund the pre-clinical program and will have an option to exclusive global rights to the product.
  • Quoin CEO, Dr. Michael Myers, said, We are extremely excited to announce our second research agreement with QUT, an institution widely acknowledged for its excellence in research.
  • Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.